Ifinatamab deruxtecan by Daiichi Sankyo for Lymphoma: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Lymphoma.

Cannabis Stocks End a Rough Year Roughly

Cannabis stocks, as measured by the Global Cannabis Stock Index, were quite volatile this year. The index gained in September, prompting a Q3 gain, but it

January 1, 2025

Only One Harm From mRNA COVID Vaccines, Report Determines

Independent reviewers confirmed a causal relationship between the first mRNA COVID-19 vaccines and myocarditis, and also determined that, more broadly, intramuscular shots can cause a

April 17, 2024

How retractions get weaponized on social media

Retractions are a sign that science is working as it should. When papers turn out to be flawed, journals typically correct the record to stem

December 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.